According to the Audit Chamber of the Russian Federation, it is necessary to study the issue of ensuring conditions for the participation of minor pharmaceutical manufacturers in public procurement. This was stated by Galina Izotova, Deputy Chairman of the Audit Chamber in an interview with RIA Novosti during the Eastern Economic Forum.
“The Audit Chamber believes that it is necessary to develop the procedures that will enable domestic pharmaceutical manufacturers with limited production capacities to participate in the procurement of medicines,” Izotova said.
The auditor noted that in 2020, medicines included in the list of vital and essential drugs were produced by 283 Russian manufacturers. Of these, 187 organizations participated in public procurement at the federal level (66%).
For many years, the participants in public procurement have been the same organizations, which are the largest pharmaceutical manufacturers, Galina Izotova emphasized.
